A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

Daewoong Pharmaceutical

Status and phase

Terminated

Phase 3

Conditions

SARS-COV-2 Infection

Covid19

Treatments

Drug: DWJ1248

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04721535

DW_DWJ1248303

Details and patient eligibility

About

To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.

Enrollment

9 patients

Sex

All

Ages

19+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Adults over the age of 19 as of the signed date in written consent
Subjects in self-quarantine who contact from COVID-19 confirmed patient
Subjects who have COVID-19 negative RT-PCR result
Subjects with no symptoms of COVID-19

Exclusion criteria

Subjects who cannot orally administer the investigational products
Subjects who need administration of immunosuppressants
Subjects who are allergic or sensitive to investigational products or its ingredients
Subjects who have a history of drug and/or alcohol abuse within 12 months before screening
Subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators